BRPI0512854A - terapia adjuvante aperfeiçoada para tumores que expressam g250 - Google Patents

terapia adjuvante aperfeiçoada para tumores que expressam g250

Info

Publication number
BRPI0512854A
BRPI0512854A BRPI0512854-4A BRPI0512854A BRPI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A
Authority
BR
Brazil
Prior art keywords
adjuvant therapy
expressing tumors
improved adjuvant
antigen
improved
Prior art date
Application number
BRPI0512854-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Olaf Wilhelm
Sven Warnaar
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Publication of BRPI0512854A publication Critical patent/BRPI0512854A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0512854-4A 2004-07-02 2005-06-29 terapia adjuvante aperfeiçoada para tumores que expressam g250 BRPI0512854A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
PCT/EP2005/006994 WO2006002889A2 (en) 2004-07-02 2005-06-29 Improved adjuvant therapy of g250-expressing tumors

Publications (1)

Publication Number Publication Date
BRPI0512854A true BRPI0512854A (pt) 2008-04-08

Family

ID=35431139

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512854-4A BRPI0512854A (pt) 2004-07-02 2005-06-29 terapia adjuvante aperfeiçoada para tumores que expressam g250

Country Status (13)

Country Link
US (1) US7691375B2 (https=)
EP (2) EP1763367A2 (https=)
JP (1) JP2008505143A (https=)
KR (1) KR101205289B1 (https=)
CN (1) CN101052416B (https=)
AU (1) AU2005259481B2 (https=)
BR (1) BRPI0512854A (https=)
CA (1) CA2566950A1 (https=)
DK (1) DK2497497T3 (https=)
ES (1) ES2641089T3 (https=)
MX (1) MXPA06013240A (https=)
RU (2) RU2371198C2 (https=)
WO (1) WO2006002889A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
KR20120082429A (ko) 2009-09-18 2012-07-23 미쓰비시 가가꾸 가부시키가이샤 간세포암 마커
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
BR112015020061A8 (pt) * 2013-02-22 2018-01-23 Wilex Ag composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
DK1733736T3 (en) * 2001-02-07 2015-06-01 Wilex Ag A process for the production of recombinant antibodies to tumors
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Also Published As

Publication number Publication date
CA2566950A1 (en) 2006-01-12
RU2371198C2 (ru) 2009-10-27
EP2497497A1 (en) 2012-09-12
JP2008505143A (ja) 2008-02-21
US20070207157A1 (en) 2007-09-06
EP1763367A2 (en) 2007-03-21
RU2519340C2 (ru) 2014-06-10
EP2497497B1 (en) 2017-06-21
MXPA06013240A (es) 2007-02-28
CN101052416A (zh) 2007-10-10
KR20070036085A (ko) 2007-04-02
AU2005259481A1 (en) 2006-01-12
CN101052416B (zh) 2013-07-10
RU2009122344A (ru) 2010-12-20
US7691375B2 (en) 2010-04-06
ES2641089T3 (es) 2017-11-07
WO2006002889A2 (en) 2006-01-12
DK2497497T3 (en) 2017-08-14
WO2006002889A3 (en) 2006-10-05
RU2007104040A (ru) 2008-08-10
AU2005259481B2 (en) 2010-04-22
KR101205289B1 (ko) 2012-11-27

Similar Documents

Publication Publication Date Title
BRPI0512854A (pt) terapia adjuvante aperfeiçoada para tumores que expressam g250
NO20084479L (no) Antitumor celleantigen antistoff terapi
BRPI0916138A2 (pt) "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
CY2017013I1 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
CR9477A (es) Numero de copias del gen del receptor del factor de crecimiento epidermico
BRPI0819916A2 (pt) Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
WO2005103081A3 (en) Human monoclonal antibodies against cd20
ATE520007T1 (de) Bildgebungsgeometrie
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
NO20092604L (no) VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament.
BR112012003809A2 (pt) anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
CY1109468T1 (el) Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
EA021242B9 (ru) Антитела к остеопротегерин лиганду (опгл)
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NO20056027L (no) Surrogat terapeutisk endepunkt for anti-CTLA-4 basert immunoterapi av sykdom
MX2009009787A (es) Mutaciones de k-ras y terapia con anticuerpos anti-egfr.
WO2009046294A3 (en) Treatment of proliferative disorders using antibodies to psma
MY147217A (en) Antibody molecules having specificity for human il-06
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: WILEX AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL